Full-body MRIs are all the rage. We take a look at three major companies offering such testing.

Private companies are capitalizing on this quest for information. Grail’s Galleri blood test screens for more than 50 ...

FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.

Whole-pelvis RT linked to improved PFS for patients with prostate cancer staged TrN0M0, while ADT linked to improved PFS in patients staged N1/M1.

New research has been published ahead-of-print by The Journal of Nuclear Medicine (JNM). JNM is published by the Society of Nuclear Medicine and Molecular Imaging, an international scientific and ...

Results from the phase 2 Daro-PET study (NCT05900973) showed that prostate-specific membrane antigen (PSMA) expression was boosted with short-course darolutamide (Nubeqa) in patients with high-risk ...

PYLARIFY TruVu™ (piflufolastat F 18) injection (also known as 18F-DCFPyL or PyL) is a fluorinated small molecule PSMA-targeted PET imaging agent that enables visualization of lymph nodes, bone and ...

New research has been published ahead-of-print by The Journal of Nuclear Medicine (JNM). JNM is published by the Society of ...

Blood tests are the most common way for health professionals to detect and diagnose a range of medical conditions. But can it ...

Recognising these subtle body changes can lead to an earlier diagnosis, when treatment is more likely to be successful ...

Artificial intelligence has bounded into the mainstream, into personal lives, classroom assignments and work meetings — so it should be no surprise to find it in doctors’ offices and emergency ...

New formulation of its widely-used U.S. market-leading PSMA PET imaging agent combines thediagnostic performance of PYLARIFY (piflufolastat F 18) with the potential for larger batches and greater pati ...